Alpha 2.0
Login Register
» Authors » Jacques Lapointe

Jacques Lapointe

Explore the profile of Jacques Lapointe including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 50
Citations 1404
Followers 0
Related Specialties
Biochemistry
Molecular Biology
Oncology
Top 10 Co-Authors
Robert Chenevert
James D Brooks
Karl-Philippe Guerard
Jonathan R Pollack
Fadi Brimo
Simone Chevalier
Sebastien P Blais
Jonathan L Huot
Daniel Y Dubois
Eleonora Scarlata
Published In
PLoS One
Nucleic Acids Res
Bioorg Med Chem
J Enzyme Inhib Med Chem
Proc Natl Acad Sci U S A
Affiliations
Soon will be listed here.
Recent Articles
1.
A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients
Ebrahimizadeh W, Guerard K, Rouzbeh S, Scarlata E, Brimo F, Patel P, et al.
Br J Cancer . 2023 Apr; 128(12):2165-2174. PMID: 37037938
Background: Distinguishing between true indolent and potentially life-threatening prostate cancer is challenging in tumours displaying clinicopathologic features associated with low or intermediate risk of relapse. Several somatic DNA copy number...
2.
Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients
Bramhecha Y, Guerard K, Audet-Walsh E, Rouzbeh S, Kassem O, Pernet E, et al.
Oncogene . 2022 Apr; 41(20):2798-2810. PMID: 35411033
Prostate cancer (PCa) metastases are highly enriched with genomic alterations including a gain at the 16p13.3 locus, recently shown to be associated with disease progression and poor clinical outcome. ECI1,...
3.
CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis
Mehra C, Chung J, He Y, Lara-Marquez M, Goyette M, Boufaied N, et al.
Commun Biol . 2021 Sep; 4(1):1042. PMID: 34493786
High mortality of prostate cancer patients is primarily due to metastasis. Understanding the mechanisms controlling metastatic processes remains essential to develop novel therapies designed to prevent the progression from localized...
4.
Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples
Ebrahimizadeh W, Guerard K, Rouzbeh S, Bramhecha Y, Scarlata E, Brimo F, et al.
J Mol Diagn . 2020 Aug; 22(10):1246-1263. PMID: 32763409
DNA copy number alterations (CNAs) are promising biomarkers to predict prostate cancer (PCa) outcome. However, fluorescence in situ hybridization (FISH) cannot assess complex CNA signatures because of low multiplexing capabilities....
5.
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Akoury E, Ahangar P, Nour A, Lapointe J, Guerard K, Haglund L, et al.
Cancer Cell Int . 2019 Feb; 19:28. PMID: 30787671
Background: Bisphosphonates (BPs) including zoledronate (zol) have become standard care for bone metastases as they effectively inhibit tumor-induced osteolysis and associated pain. Several studies have also suggested that zol has...
6.
The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy
Bramhecha Y, Rouzbeh S, Guerard K, Scarlata E, Brimo F, Chevalier S, et al.
Mod Pathol . 2018 Aug; 32(1):128-138. PMID: 30140035
Prostate cancer is a clinically heterogeneous disease and accurately risk-stratifying patients is a key clinical challenge. We hypothesized that the concurrent identification of the DNA copy number alterations 10q23.3 (PTEN)...
7.
Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention
Bramhecha Y, Guerard K, Rouzbeh S, Scarlata E, Brimo F, Chevalier S, et al.
Mol Cancer Res . 2017 Oct; 16(1):115-123. PMID: 28993510
Identifying tumors with high metastatic potential is key to improving the clinical management of prostate cancer. Recently, we characterized a chromosome 16p13.3 gain frequently observed in prostate cancer metastases and...
8.
Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer
Audet-Walsh E, Dufour C, Yee T, Zouanat F, Yan M, Kalloghlian G, et al.
Genes Dev . 2017 Jul; 31(12):1228-1242. PMID: 28724614
Androgen receptor (AR) signaling reprograms cellular metabolism to support prostate cancer (PCa) growth and survival. Another key regulator of cellular metabolism is mTOR, a kinase found in diverse protein complexes...
9.
Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores
Patel P, Selvarajah S, Guerard K, Bartlett J, Lapointe J, Berman D, et al.
PLoS One . 2017 Jun; 12(6):e0179732. PMID: 28640876
Cancer biomarker studies often require nucleic acid extraction from limited amounts of formalin-fixed, paraffin-embedded (FFPE) tissues, such as histologic sections or needle cores. A major challenge is low quantity and...
10.
Inhibition of Helicobacter pylori Glu-tRNA amidotransferase by novel analogues of the putative transamidation intermediate
Pham V, Maaroufi H, Balg C, Blais S, Messier N, Roy P, et al.
FEBS Lett . 2016 Sep; 590(19):3335-3345. PMID: 27586694
Glutaminyl-tRNA in Helicobacter pylori is formed by an indirect route requiring a noncanonical glutamyl-tRNA synthetase and a tRNA-dependent heterotrimeric amidotransferase (AdT) GatCAB. Widespread use of this pathway among prominent human...